MARKET

ADAG

ADAG

Adagene Inc.
NASDAQ
2.670
+0.090
+3.49%
After Hours: 2.720 +0.05 +1.87% 19:30 10/28 EDT
OPEN
2.750
PREV CLOSE
2.580
HIGH
2.780
LOW
2.610
VOLUME
235.91K
TURNOVER
--
52 WEEK HIGH
4.850
52 WEEK LOW
1.300
MARKET CAP
179.27M
P/E (TTM)
-7.0879
1D
5D
1M
3M
1Y
5Y
1D
Adagene Begins Phase 1 Trial Of Muzastotug Plus INCA33890 In MSS Colorectal Cancer; Stock Up
NASDAQ · 18h ago
Adagene Is Maintained at Buy by Chardan Capital
Dow Jones · 19h ago
Adagene Price Target Maintained With a $9.00/Share by Chardan Capital
Dow Jones · 19h ago
Adagene doses first patient in muzastotug, INCA33890 combination study
TipRanks · 20h ago
Weekly Report: what happened at ADAG last week (1019-1023)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Sarepta Therapeutics (SRPT) and Adagene (ADAG)
TipRanks · 10/19 10:30
Adagene Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 10/19 10:27
HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target
Benzinga · 10/19 10:17
More
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Webull offers Adagene Inc (ADR) stock information, including NASDAQ: ADAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAG stock methods without spending real money on the virtual paper trading platform.